U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy
Biospace,
NEW YORK--( BUSINESS WIRE )-- Pfizer, Inc. (NYSE: PFE) today announced that the U.S.